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ABSTRACT 27 
 28 
In women with endometriosis the lifetime risk of ovarian cancer is increased from 1.4% to about 29 
1.9%. The risk of clear cell and endometrioid ovarian cancer is, respectively, tripled and doubled. 30 
Atypical endometriosis, observed in 1-3% of endometriomas excised in premenopausal women, is 31 
the intermediate precursor lesion linking typical endometriosis and clear cell/endometrioid tumors. 32 
Prolonged oral contraceptive use is associated with a major reduction in ovarian cancer risk among 33 
women with endometriosis. Surveillance ± progestogen treatment or surgery should be discussed in 34 
perimenopausal women with small, typical endometriomas. In most perimenopausal women with a 35 
history of endometriosis but without endometriomas, surveillance instead of risk-reducing bilateral 36 
salpingo-oophorectomy seems advisable. Risk-reducing salpingo-oophorectomy might benefit 37 
patients at particularly increased risk, but the evidence is inconclusive. Risk profiling models and 38 
decision aids may assist patients in their choice. Screening of the general perimenopausal 39 
population to detect asymptomatic endometriomas is unlikely to reduce disease-specific mortality. 40 
 41 
 42 
KEYWORDS 43 
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1.  INTRODUCTION 47 
 48 
Endometriosis is associated with a moderate increase in ovarian cancer risk. According to large 49 
population-based studies and meta-analyses of cohort and case-control studies, the overall relative 50 
risk varies from 1.4 to 1.8 [1-3]. The risk of ovarian cancer appears particularly elevated among 51 
subjects with a long-standing history of untreated ovarian endometriosis [4-9]. The main objectives 52 
of this review are i) to suggest a management plan for perimenopausal patients with ovarian 53 
endometriomas, and ii) to clarify whether perimenopausal women with a history of endometriosis 54 
but without current endometriomas would benefit from prevention interventions in terms of reduced 55 
mortality from endometriosis-associated ovarian cancer (EAOC). To this aim, relevant 56 
epidemiological and oncological information has been critically reviewed. In this regard, several 57 
excellent articles are available on the pathogenesis and classification of ovarian cancers [10-13]. 58 
 For the purpose of the present review, some definitions need preliminary clarification.  59 
Perimenopause is defined by the World Health Organization and the North American Menopause 60 
Society as the two to eight years preceding menopause and one year following final menses [14,15]. 61 
The age of 45 years is here considered as the lower limit of the perimenopausal period. 62 
Endometriomas are defined as typical or atypical based on published ultrasonographic 63 
characteristics [16-18]. In the absence of a precise measure consistently indicated by international 64 
gynecological and radiological societies, endometriomas are considered as small or large based on 65 
the maximum cut-off diameter of 5 cm suggested by Muzii et al. [19]. In addition, the association 66 
between endometriosis and specific epithelial ovarian cancer histotypes is assumed to be causal. 67 
This view is supported by a large body of evidence and shared by most, albeit not all, authoritative 68 
experts in the field [1-3, 10-13]. 69 
 70 
2.  EPIDEMIOLOGICAL AND HISTOPATHOLOGICAL OUTLINE OF THE ASSOCIATION 71 
BETWEEN ENDOMETRIOSIS AND OVARIAN CANCER 72 
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A woman’s lifetime risk of developing ovarian cancer is about 1 in 75 [13]. In western countries ≥ 73 
90% of ovarian malignancies are epithelial in origin. According to the dualistic pathogenic model 74 
[11], the main epithelial ovarian cancer histotypes are classified as type I and II. The former group 75 
comprises the so-called endometriosis-associated tumors that include endometrioid, clear cell, and 76 
seromucinous carcinomas. Type II tumors are mainly composed of high-grade serous carcinomas 77 
(HGSOC), which represent almost 70% of ovarian carcinomas [11]. Among the EAOC, the 78 
seromucinous histotype is fairly rare. Thus, the endometrioid ovarian carcinomas (ENOC) and the 79 
clear cell ovarian carcinomas (CCOC) are the most frequent histotypes associated with 80 
endometriosis. In particular, it has been suggested that ENOC derive from cells of the secretory cell 81 
lineage, whereas CCOC derive from, or have similarities to, cells of the ciliated cell lineage [20]. 82 
 Women with endometriosis are at about tripled risk for CCOC and doubled risk for ENOC 83 
[1]. The prevalence of CCOC is variable, depending on the geographic area considered. In fact, 84 
figures between 1% and 13% have been reported in Europe and North America, and between 15% 85 
and 25% in some Asian region, particularly in Japan [21]. The prevalence of ENOC varies between 86 
7% and 13% in surgical series. A synchronous carcinoma of the eutopic endometrium has been 87 
reported in 15% to 20% of cases of ENOC, thus suggesting a common origin or common risk 88 
factors [22]. Overall, CCOC and ENOC are, respectively, the second and third most common 89 
ovarian cancer histotypes. They represent about 20% of all ovarian carcinomas, but account for no 90 
more than 10% of the deaths from this disease, whereas HGSOC accounts for about 90% of the 91 
deaths [11,13,22]. This seems partly due to the fact that most CCOC and ENOC are detected at 92 
early stages, when the 5-year survival rate is around 90%, whereas HGSOC are usually detected at 93 
advanced stages, with a 5-year survival rate of about 30% [23,24]. 94 
 This striking difference in stage at detection between EAOC and HGSOC seems to be 95 
related to different biological behaviors, but also to different pathogeneses and the fact that a 96 
precursor lesion is identifiable for CCOC and ENOC, but not for HGSOC. In fact, according to the 97 
dualistic model, most HGSOC derives from minute and undetectable atypical lesions within the 98 
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fimbriated end of the fallopian tube (serous tubal intraepithelial carcinomas, STIC) [25]. When 99 
malignant cells exfoliate from STIC, they implant not only on the ovaries, but also on the 100 
peritoneum, the omentum, and on abdominopelvic organs. Therefore, most HGSOC develop as late 101 
stage cancers from inception. Conversely, most CCOC and ENOC would arise within ovarian 102 
endometriotic cysts that are detectable at transvaginal ultrasonography (TVUS), and are confined to 103 
the ovary for a variable period of time [11]. Thus, when only one ovary is involved and surgery is 104 
promptly undertaken, the disease is usually at stage I. 105 
 Based on the lifetime risk of developing ovarian cancer in western countries, i.e., 1/75 106 
(1.33%), the magnitude of the potential effect of untreated ovarian endometriotic cysts can be 107 
tentatively calculated. Considering a prevalence of HGSOC, CCOC, ENOC and “other” histotypes 108 
of, respectively, 70%, 10%, 10%, and 10% among ovarian cancers arising in the general female 109 
population [13,22], and hypothesizing that the relative risk of developing CCOCs, ENOCs and 110 
“other” histotypes is, respectively, 3, 2, and 1.5 in women with endometriosis, the lifetime risk of 111 
developing an ovarian cancer in this latter sub-population would be 1/56 (1.79%; difference with 112 
the general female population = +0.46%). This is in line with literature findings [1-3]. 113 
Hypothesizing an overall percent survival for HSGOC, CCOC, ENOC and “other” histotypes of, 114 
respectively, 20%, 35%, 55%, and 35%, yields a rough lifetime risk of dying from ovarian cancer of 115 
1/100 (1%) in the general female population [13], and of 1/77 (1.31%) in postmenopausal women 116 
with untreated ovarian endometriosis (difference with the general female population = +0.31%). 117 
These estimates may vary according to the geographical area considered. They are herein calculated 118 
only to provide an approximation of the potential epidemiological burden. 119 
  120 
3.  MOLECULAR AND GENETIC OUTLINE OF ENDOMETRIOSIS-ASSOCIATED 121 
OVARIAN CANCER  122 
Molecular pattern of endometriosis-associated ovarian cancers 123 
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It is puzzling how endometriosis can be the precursor tissue of two distinct ovarian cancer 124 
histotypes without any recurrent genetic mutation that is unique to either of them (Table 1). The 125 
differences in the genomic landscape features between ENOC and CCOC are not absolute. Thus, 126 
mutations alone cannot explain their clinical and phenotypic distinctions and the ovarian 127 
environment is likely to play a critical role [20]. 128 
Ovarian cancer is considered as a hormone-responsive cancer [26]. However, one of the 129 
predominant and clinical relevant aspect distinguishing these two histotypes is the differential 130 
estrogen receptor expression. The progesterone receptor and estrogen receptor (ER) mediate some 131 
effects of female steroid hormones on proliferation and apoptosis of ovarian cancer cells. Actions of 132 
estradiol are mediated by two isoforms of ERs: ERα and ERβ that differ not only in their tissue 133 
distribution, but also in their ligand binding specificity and affinity [26]. Besides subtypes, the 134 
presence of ERβ variants (β1-β5) due to alternative splicing, further complicates the biological 135 
significance of ERβ signaling. ERβ1 is the only isoform capable of binding ligands while ERβ2 and 136 
ERβ5 can heterodimerize with ERβ1 and induce its transcriptional activity ligand-dependently [27].  137 
Cytoplasmic ERs are also known to exert effects through nongenomic signaling [26,27]. ERα has 138 
been shown to represent an independent prognostic marker for ENOC [28] while nuclear ERα was 139 
barely detectable in CCOC. Significant loss of cERβ2 and of cERβ5 expression was also observed 140 
in CCOC (Table 1). An improved survival in patients with hormone-receptor-positive tumors has 141 
been reported, partly explained by increased numbers of patients who respond to endocrine 142 
treatments [28]. 143 
Although some mutations are present in both histotypes, there are however important 144 
molecular differences between CCOC and ENOC: 145 
 Inactivating ARID1A mutations are the most common molecular genetic alteration reported 146 
thus far in CCOC and ENOC, but a higher frequency of ARID1A mutations has been detected in 147 
CCOC (46–57%) compared with ENOC (30%) [29]. These mutations result in loss of expression of 148 
the protein encoded by ARID1A (BAF250a) which normally suppresses cellular proliferation 149 
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through a p53-dependent transcription regulation of several tumor suppressors including CDKN1A 150 
(encoding p21) and SMAD3 [30]. As a matter of fact, loss of protein expression of the ARID1A 151 
tumor suppressor gene has been demonstrated in endometriosis adjacent to clear cell tumor samples 152 
[31]. According to Yamamoto and coworkers, ARID1A protein immunoreactivity was deficient in 153 
17 (61%) of the 28 CCOC [32]. According to Ayhan et al., loss of ARID1A staining was observed 154 
in 75% of the 24 CCOC adjacent to endometriomas [33]. Stamp et al. found that the incidence of 155 
BAF250a loss was 55% in CCOC and 33% in ENOC [34]. Interestingly, mutations in ARID1A or 156 
loss of BAF250a expression have not been shown to be associated with a different cancer 157 
phenotype or prognosis in EAOC. No differences in the clinical behavior were observed comparing 158 
BAF250a-positive versus BAF250a-negative cancers supporting the idea that ARID1A mutations 159 
might represent a marker of genomic instability without driving the phenotype [35]. 160 
Overexpression of the transcription factor HNF-1beta and PIK3CA mutations are also 161 
common in CCOC [34,35]. Using whole-genome shotgun sequencing of 7 CCOC and targeted 162 
sequencing in synchronous endometriosis, 98% of somatic mutations were found in common 163 
between carcinomas and endometriotic lesions. ARID1A and PIK3CA mutations appeared 164 
consistently in concurrent endometriosis when present in the primary CCOC [24,36]. Importantly, 165 
aberrant expression of ARID1A, PIK3CA, and NF-kB genes has been recognized as the major 166 
target genes involved in oxidative stress-induced carcinogenesis and, in the context of the malignant 167 
transformation of endometriosis, the high oxidative potential of iron has been emphasized [34]. 168 
 Menstrual red blood cells in the extravascular space tend to lyse quickly and, as a result of 169 
hemoglobin oxidization, heme is released. Free heme promotes oxidative damage and formation of 170 
reactive oxygen species (ROS), which, in turn, split the heme ring and release redoxactive free iron. 171 
Free iron is a strong oxidant and, when present at high levels, contributes to the production of ROS 172 
[37-41]. A fine-tuned regulation of lethal and sublethal oxidative stress responses might modulate 173 
either cell death or tumor initiation, respectively, due to the iron-induced DNA damage, mutations, 174 
and genomic instability. Under the proliferative stress generated by iron and oxidative stress, 175 
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endometriotic cells can escape apoptosis under the up-regulation of the transcription factor HNF-176 
1beta expression and subsequently re-enter the cell cycle with genotoxic stress. Mutations in 177 
ARID1A gene and subsequent protein alteration may result in a defective repair or replication of 178 
damaged DNA. Activating mutations of the PIK3CA gene lead to activation of the AKT pathway 179 
resulting in improved cancer cell growth, survival and invasion [34]. AKT phosphorylation is also 180 
associated with ARID1A/BAF250a deficient tumors [35]. In line with this hypothesis and with the 181 
reduction of the hormone dependency of CCOC, oxidative stress has been shown to act as a 182 
physiological regulator of ERs [34]. 183 
 A more complex scenario may be foreseen for ENOC based on recent molecular, 184 
epidemiologic and histopathologic studies [42]. Endometrioid ovarian cancers possess different 185 
clinical characteristics when compared to cancers that are not associated with the disease. Patients 186 
with ENOC are younger and are more likely to have low grade and early-stage tumors which are 187 
more frequently synchronous to endometrial carcinomas. The fact that synchronous endometrial 188 
and ovarian tumors are no longer considered the result of two independently occurring, 189 
simultaneous tumors, but are rather clonally derived, opens a new scenario on the origin and/or 190 
spread of endometriosis-associated tumors. Site of origin and directionality of metastasis, as well as 191 
the specific ovarian and endometrial microenvironment features that may influence progression are 192 
however yet to be clarified [43].  193 
Major genetic alterations involved in ENOC are represented by PTEN, ARID1A, KRAS and 194 
CTNNB1 gene mutations [42]. Mutations in exon 3 of the gene encoding β-catenin (CTNNB1) 195 
were identified in 21 (60%) of 35 ENOC, but were not identified in any of the 28 CCOC 196 
investigated by Matsumoto and coworkers [44]. Mutations in PTEN gene were identified in 20% of 197 
ENOC and in 8.3% of CCOC [45]. KRAS mutations were identified in 12 (29%) of 42 ENOC [46]. 198 
Mutations in the KRAS gene lead to constitutive activation of the KRAS-BRAF-MEK-MAPK 199 
signaling pathway and the resulting sustained MAPK activity has myriad effects on cell function, 200 
including cellular proliferation, apoptosis, adhesion and migratory capacity. 201 
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Cancer driver mutations in endometriosis 202 
The transformation of a normal cell into a cancer cell is due to the progressive acquisition of driver 203 
mutations. Several studies have evaluated somatic cancer-associated mutations in endometriotic 204 
lesions without concurrent cancer in order to assess whether endometriosis might be considered as a 205 
precursor of cancer [45]. While TP53 mutations are absent in solitary ovarian endometriotic cysts 206 
[45], PTEN mutations were found in 20% and 53% of these lesions in two different studies [47,48]. 207 
Loss of ARID1A/BAF250a has been observed quite rarely in non-atypical endometriosis (from 0 to 208 
20% of samples) while atypical endometriosis was found to be ARID1A/BAF250a negative in a 209 
variable proportion of cases according to different studies (from 10% to 100%) [23,34,49]. No 210 
PIK3CA mutations were observed in 23 endometriotic samples [23]. Interestingly, KRAS and 211 
ARID1A mutations have been recently detected in deep infiltrating endometriotic lesions that very 212 
rarely undergo malignant transformation [50]. This poses some doubts on the real oncogenic 213 
potential of these mutations. As correctly pointed out by Chui and co-workers, the role of cancer 214 
driver mutations has still to be elucidated as well as the correlation between the genotype and the 215 
clinical outcomes [51]. 216 
 217 
4. IS OVARIAN ENDOMETRIOSIS A PREMALIGNANT LESION? 218 
As the lifetime risk of developing an adenocarcinoma of the endometrium is about 2% in the 219 
general female population, there seems to be no reason to believe that the same type of mucosa 220 
should not undergo malignant derailments at a similar rate when displaced at ectopic sites. Indeed, 221 
EAOC have been described as endometrial cancers in the wrong place [12]. The chronic 222 
inflammatory pelvic environment of women with endometriosis may theoretically even facilitate 223 
the transformation of a normal endometrial cell into a malignant cell. However, determining 224 
whether the mere presence of endometrium at ectopic sites should be considered per se a 225 
premalignant condition seems crucial and constitutes the conceptual base of any strategy aimed at 226 
reducing EAOC mortality. Lesions are defined “precancerous” based on definite epidemiologic, 227 
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morphologic, molecular, and biologic criteria that imply the acquisition of genetic, karyotypic, 228 
structural, or functional changes in a cluster of cells that differentiate them from the surrounding 229 
normal tissue [52]. In other words, premalignant lesions should reflect an intermediate stage along 230 
the pathway leading to cancer. When enough genetic changes have occurred, modifications in 231 
appearance and function are observed, but not yet associated with the typical malignant behavior. 232 
Examples includes actinic keratosis, Barrett's esophagus, atrophic gastritis, ductal carcinoma in situ, 233 
and cervical dysplasia [52]. 234 
 In 2004 the National Cancer Institute and The George Washington University Cancer 235 
Institute convened a conference of expert pathologists with the objective of reaching a consensus on 236 
the definition of precancerous lesions. Based on the premise that the identification and elimination 237 
of specific cancer precursors would lead to the near-eradication of that type of cancer, it was agreed 238 
that the detection of premalignant lesions should not necessarily be based exclusively on histologic 239 
criteria. In order to demonstrate the effect of any prevention intervention, it is crucial to 240 
appropriately define a precancer independently of detection methods adopted. The five developed 241 
defining criteria that must be applied to precancerous lesions are reported in Table 2. According to 242 
the authors of the consensus document, “these five criteria represent the minimal set of conditions 243 
for a lesion detected by any method to be considered a precancer. These conditions are necessary 244 
and sufficient. All of the criteria must apply, and they all must apply concurrently (i.e. not additive 245 
over time)” [52]. One of the novelties here is that the definition of precancer lesions is not entirely 246 
based on specific morphologic features, but also on cytogenetic, molecular, and even behavioral 247 
(phenotypic) characteristics.  248 
 Although all the criteria must simultaneously apply, the third and the fifth ones seems 249 
particularly relevant for the endometriosis population. According to the third criterion, a 250 
precancerous lesion must be different from the normal tissue from which it arises. In other words, 251 
the “normal”, although displaced, endometrium cannot be considered a precancerous lesion. If 252 
intrauterine endometrium is the source of the ectopic mucosa, then the usual intermediate steps 253 
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leading to endometrial cancer (atypical hyperplasia; endometrial intraepithelial neoplasia) should be 254 
expected to occur also when the endometrium is located in the pelvis before an “ovarian” cancer 255 
develops. Distinguishing premalignant lesions from normal endometrial tissue, malignant tissue, 256 
and other lesions is important. As an example, in ovarian endometriotic cysts it is sometimes 257 
cumbersome to discriminate between the true cytological/structural atypia and the benign reactive 258 
atypia associated with underlying inflammation (Figure 1) [53,54]. 259 
 Several authors indicate only atypical endometriosis, and not normal endometrium at ectopic 260 
sites, as a premalignant lesion. Kommoss and Gilks [55] maintain that the assumed precursor of 261 
ENOC and CCOC is atypical endometriosis resulting from ovarian implantation of endometrial 262 
tissue after trans-tubal spread. Anglesio and Wilbur [24,54] specifies that cytologically atypical 263 
ovarian endometriosis (large nuclei that are either hyperchromatic or pale, have an increased 264 
nucleus-to-cytoplasm ratio, cellular crowding, stratification, or tufting) should be considered the 265 
direct precursor of CCOC and ENOC, as atypical endometriosis has been identified contiguous with 266 
these tumor histotypes [56]. Samartzis et al. [23] maintain that atypical endometriosis should be 267 
considered the histological precursor lesion of CCOC, as common truncating mutations and loss of 268 
protein expression of the ARID1A tumor suppressor gene have been demonstrated in these tumors 269 
and in contiguous atypical endometriosis. However, as previously mentioned, these mutations can 270 
also be found in deep infiltrating endometriosis that, according to Anglesio et al. [50], is not a 271 
cancer precursor. Indeed, according to the results two systematic literature reviews, only a few 272 
cases of carcinomas arising in rectovaginal endometriotic lesions have been reported [57,58].  273 
 Therefore, a specific role seems to be played by the ovarian microenvironment in increasing 274 
the risk of malignant derailment [20]. Karnezis concurs that the ovarian microenvironment seems to 275 
be essential for the malignant transformation of endometriosis because many endometriotic lesions 276 
are located outside the ovary, including the pelvic peritoneum, but carcinomas at such sites are rare 277 
[12]. In this regard, Blanco et al. observed that the stroma surrounding ovarian epithelial tumors is 278 
activated to elaborate steroid hormones which may stimulate further neoplastic growth [59]. 279 
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 Kurman et al. [11] defined the eutopic endometrium as the precursor site of origin of CCOC 280 
and ENOC, endometriosis as the potential precursor lesion, and atypical endometriosis as the 281 
immediate precursor lesion. Karnezis indicates endometriosis as the tissue of origin of ENOC and 282 
CCOC, endometrial epithelial cells as the cells of origin, and endometrioid borderline tumors as the 283 
precursor lesion [12]. According to these views, ectopic endometrium, similarly to the eutopic 284 
counterpart, has the potential for malignant derailment, but should not be considered a precancer. In 285 
addition, Karnezis [12] categorized endometriosis as “high risk” and “low risk”, based on the 286 
presence of atypical endometriosis, intended as an intermediate precursor that links typical 287 
endometriosis and ovarian cancers.  288 
 Therefore, given the current consensus on the very low malignant potential of peritoneal 289 
endometriosis, be it “superficial”, as in early disease stages, or “deep”, as in rectovaginal plaques, 290 
efforts should be focused on the identification of those ovarian endometriotic cysts that include 291 
atypical epithelial lesions.  292 
 Here the fifth criterion for the definition of premalignant lesions states that there must be a 293 
method by which the precancer can be diagnosed. According to the authors, “this requirement is not 294 
constrained by the diagnostic method, which today is primarily routine histopathologic examination 295 
of excisional biopsies. Any single or combinatorial diagnostic modality with sufficient sensitivity 296 
and specificity that is clinically useful may fulfill this requirement. Functional imaging and 297 
molecular analysis of biologic samples are examples of emergent technology that might be useful in 298 
this regard” [52]. This is an important area of future endometriosis research, as the possibility of 299 
identifying those endometriomas that harbor atypical epithelial foci would allow, on one hand 300 
timely surgery with prevention of lesion progression, and on the other hand conservative 301 
management with reduction of morbidity and cost in the majority of women in whom premalignant 302 
lesions can be reliably ruled out. 303 
 304 
5.  EARLY DETECTION OF ENDOMETRIOSIS-ASSOCIATED OVARIAN TUMORS 305 
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An in-depth description of ultrasonographic characteristics of the spectrum of ovarian lesions 306 
ranging from the so-called “typical” benign ovarian endometrioma to overtly suspicious masses 307 
originating from endometriotic cysts is beyond the scope of the present review, and the reader may 308 
refer to several authoritative articles, including those by Exacoustos et al. [16] and Guerriero et al. 309 
[17,18]. Here only summary information is given regarding some elements that may increase the 310 
awareness towards a possible malignant derailment of ovarian endometriosis. 311 
 According to Exacoustos et al. [16], the ‘typical’ endometrioma is a unilocular or 312 
multilocular (one to four locules) cyst, with homogeneous low-level echogenicity (ground glass 313 
echogenicity) of the cyst fluid, no solid parts, and no papillations with detectable blood flow, 314 
detected in a premenopausal woman. Papillary projections are protrusion of solid tissue into the cyst 315 
lumen with a height of 3 mm or more. The ultrasonographic characteristics of endometriomas may 316 
differ according to pre- or postmenopausal status. Endometriotic cysts in postmenopausal women 317 
are more frequently multilocular, and less likely to exhibit ground glass echogenicity, as anechoic 318 
cyst fluid or cyst fluid with mixed echogenicity is often observed [16]. Guerriero et al. confirmed 319 
that in older women multilocular cysts and cysts with papillations and other solid components 320 
become more common whereas ground glass echogenicity of cyst fluid becomes less common 321 
compared with endometriomas observed in younger women. Interestingly, the maximal cyst 322 
diameter does not seem to vary significantly with age [18]. 323 
 Nezhat et al. warns that an increase in endometrioma size in postmenopause or during 324 
hormonal therapy in premenopause, modification of ultrasonographic characteristics, and 325 
appearance of mural node formation constitute ominous signs that require surgical excision [10]. 326 
Relapsing or worsening pelvic pain symptoms, such as newly developed dysmenorrhea and 327 
dyspareunia, should further increase the index of suspicion [23]. Advancing age (≥ 45 years) and 328 
the size of endometriomas (≥ 8 cm) were independent predictors of development of ovarian cancer 329 
among women with ovarian endometrioma [6,7,60]. 330 
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 At TVUS, borderline tumors and carcinomas arising from endometriotic cysts generally 331 
show a vascularized solid component [16]. Tanase et al. [61] reported that, whereas in 332 
premenopausal women the majority of mural nodular lesions observed within ovarian 333 
endometriomas were retracted blood clots, in older women and those with larger cyst diameters, 334 
mural nodules were more likely malignant, especially in case of large nodule sizes and taller than 335 
wider lesions. Also in the study by Taniguchi et al. [62] the rapid growth of an endometrioma and 336 
the presence of mural nodules were the most reliable predictors of malignancy.  337 
In the large series of Kuo et al. [63], the frequency of unexpected EAOC in presumed ovarian 338 
endometriomas was 0.14%. All patients with malignancies were aged ≥ 40 years and almost two 339 
thirds of them had vegetations within the ovarian cyst at preoperative ultrasonography. 340 
 Evaluation of all suspicious endometriomas by gynecologists or radiologists with specific 341 
oncological experience may greatly increase the performance of imaging techniques in the detection 342 
of those cysts that requires prompt surgical removal. In this regard, according to the 343 
recommendations of the First International Consensus Report on Adnexal Masses, “despite 344 
extensive research into various risk prediction models, subjective assessment in the hands of an 345 
expert remains as accurate as any technique for assessment of adnexal masses by sonography. 346 
Thus, it is appropriate to consider referral to an expert gynecologic sonologist when faced with a 347 
challenging or indeterminate adnexal mass” [64]. 348 
 Of relevance here, the debate on ultrasonographic signs of malignancy does not shed light 349 
on the possibility of identifying premalignant endometriomas, i.e. endometriomas harboring 350 
atypical lesions. Ultrasonographic findings may significantly differ between endometriomas 351 
degenerated into cancer and endometriomas with atypical lesions. Specific studies aimed at 352 
disentangling this issue are currently lacking and represent a research priority. Noteworthy, this 353 
kind of studies should rely on vast series of women, as atypical endometriosis is rare, and should be 354 
prospectively undertaken in centers systematically performing a thorough and detailed pre-surgical 355 
TVUS evaluation following a standardized methodology [18].   356 
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6.  MANAGEMENT OF PERIMENOPAUSAL WOMEN WITH OVARIAN 357 
ENDOMETRIOMAS  358 
When a typical ovarian endometrioma of < 5 cm is identified in a young woman seeking conception 359 
in the future, the risk of iatrogenic ovarian reserve reduction may suggest refraining from surgery 360 
[19]. Moreover, when surgery for endometriomas is chosen in women of < 45 years of age, gonadal 361 
conservation may be preferable even when pregnancy desire is no longer an issue, as premature 362 
hypo-estrogenism may increase the risk of cardiovascular events and all-cause mortality [65]. 363 
However, when women approach the menopause, the reproductive and hormonal benefits deriving 364 
from surgical abstention or conservative procedures progressively vanish. Therefore, removal of 365 
ovaries with endometriotic cysts may be discussed in perimenopausal women.  366 
  Unfortunately, no robust information is available on the effect of surveillance compared 367 
with that of surgery (unilateral salpingo-oophorectomy or cystectomy/partial ovarian excision) on 368 
mortality from EAOC in patients with endometriosis/endometriomas. According to the results of a 369 
case-control study conducted by Rossing et al. [8], the risk of invasive epithelial ovarian cancer 370 
varied according to performance of ovarian surgery after the diagnosis of endometriosis. In fact, 371 
with respect to women without a history of endometriosis, the OR of ovarian cancer was 1.6 (95% 372 
CI: 1.1–2.3) among women with endometriosis who did not undergo surgery, and 1.2 (95% CI: 0.5–373 
2.5) among those who did. Moreover, only unilateral salpingo-oophorectomy appeared protective 374 
(OR, 0.8; 95% CI: 0.3–2.1), whereas cystectomy/partial ovarian excision was not (OR, 3.3; 95% CI: 375 
0.7–15.3). In particular, the OR of ENOC and CCOC was 3.2 (95% CI: 1.9–5.6) among women 376 
with a history of endometriosis with no subsequent ovarian surgery, compared with 1.6 (95% CI: 377 
0.4–5.7) among those who underwent ovarian surgery. However, the small number of cases limited 378 
the precision of the estimates. In fact, only 94 women with a history of endometriosis were included 379 
in this study, and only 20 of them underwent previous ovarian surgery. 380 
 In the nested case-control study by Melin et al. [9], all women with a first-time discharge 381 
diagnosis of endometriosis in the period 1969–2007 were identified using the National Swedish 382 
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Patient Register, and all women diagnosed with epithelial ovarian cancer at least one year after the 383 
endometriosis diagnosis (cases) were identified by linkage to the National Swedish Cancer Register. 384 
Matched controls were randomly selected from the study base. A significant association was 385 
observed between unilateral salpingo-oophorectomy, as well as radical excision of all visible 386 
endometriosis, and ovarian cancer risk (adjusted OR, 0.19; 95% CI 0.08–0.46 and 0.30; 95% CI 387 
0.12–0.74, respectively). Unfortunately, no information has been provided on ovarian cancer 388 
histotype, thus the effect of unilateral salpingo-oophorectomy is expected. Moreover, the 389 
categorization of radical versus non-radical endometriosis excision was based on retrospective 390 
review of surgical notes.  391 
 In case unilateral salpingo-oophorectomy is performed, the risk of overall ovarian cancer 392 
mortality is reduced by definition, but this effect may be largely due to a decrease in the risk of 393 
death from HGSOC following salpingectomy, rather than from CCOC and ENOC following 394 
removal of ovaries with endometriomas. Therefore, the results of the above two studies do not 395 
definitively clarify whether surgery specifically aimed at removing ovaries with endometriomas is 396 
better than surveillance, in terms of reduced mortality from EAOC, for perimenopausal 397 
endometriosis patients. 398 
 Consequently, two different clinical approaches may be envisaged in perimenopausal 399 
women with small (< 5 cm), typical endometriomas, i.e., i) removal of the affected ovary/ovaries 400 
plus bilateral salpingectomy, especially in cases of long-standing endometriomas in women who are 401 
not using OC or progestogens, or ii) strict surveillance ± progestogen treatment with immediate 402 
surgery in case of modifications of ultrasonographic cyst patterns (e.g., cyst volume increase and 403 
appearance of septa, papillary projections, mural nodules, or changes in vascularization), or 404 
suspicious rise in serum CA 125 and human epididymis protein 4 (HE4) levels. In theory, 405 
surveillance could be justified by the fact that endometriosis-related cancers usually remain intra-406 
cystic for a variable period of time [11,22].  407 
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 The median age at diagnosis of ENOC and CCOC is, respectively, 47 and 55 years 408 
[21,22,23]. Therefore, the effect size of surgery is likely directly related with the age at which the 409 
affected ovaries are removed. Surgery should be considered in case of long-standing 410 
endometriomas [4-7], especially if they are not being treated with oral contraceptives (OC) or 411 
progestogens, but also in case of de-novo detection of an endometrioma during medical treatment, 412 
as the risk of malignancy appears here substantially increased [7,61,63]. Moreover, according to 413 
Haraguchi et al. [66] recurrent endometriomas are at especially augmented risk of malignant 414 
transformation, as all EAOC in their series developed in patients who experienced a cyst 415 
recurrence.  416 
 Not removing the ovary with endometriotic cysts means that perimenopausal women should 417 
undergo periodic TVUS and serum marker level measurements for many years. In addition, the 418 
variable degree of anxiety caused by knowing of being at increased risk for a dreadful cancer 419 
should be carefully weighed. These factors augment the overall burden of treatment, including out-420 
of-pocket costs, and may unfavorably impact on health-related quality of life [67]. On the other 421 
hand, the patient medical history must be considered because, especially when multiple and 422 
extensive abdominopelvic procedures have been performed, the operative risk may be increased to 423 
the point that sometimes the balance may be tipped toward expectant management. Removing the 424 
adnexa when previous surgical notes report the presence of extensive and dense pelvic adhesions 425 
with difficult visualization of the internal genitalia (frozen pelvis), exposes to an increased risk of 426 
bowel and ureteral lesions, as well as of the ovarian remnant syndrome [68]. In case surgical 427 
abstention is chosen, progestogens may be used as a therapeutic measure during surveillance, after 428 
information is provided on the potential benefits and potential harms of combining periodic 429 
assessments with medical therapy in specific clinical conditions. Regrettably, insufficient data are 430 
available on variation of EAOC risk when hormonal treatments are started during perimenopause. 431 
Suspicious modifications of TVUS appearance or increase in cyst size during suppressive medical 432 
therapy requires prompt surgical exploration. 433 
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 A further aspect to be discussed with the perimenopausal patient with deep lesions in 434 
addition to ovarian endometriomas is whether, in case bilateral salpingo-oophorectomy is decided, 435 
deep lesions should also be removed. Symptoms must guide the choice, as only persistent pain 436 
despite hypo-estrogenizing medical treatment justifies the additional surgical risk of excising 437 
lesions that very rarely undergo malignant transformation and that will most likely become 438 
quiescent after gonadal removal. In case the ovaries are removed, but deep lesions are left in place, 439 
tibolone or combinations including a progestogen should be used in women requesting hormone 440 
replacement therapy [69]. 441 
 All the above information should be provided to perimenopausal patients with 442 
endometriomas, and uncertainties should be openly discussed. No robust evidence seems to exist to 443 
support either surveillance or surgery in all women with small, typical endometriomas. A 444 
commonsense approach may be adopted in these circumstances, that is, suggesting surveillance in 445 
patients at high surgical risk, and surgery in those at average surgical risk. If surveillance is chosen 446 
in women not using medical therapies, the possibility of starting treatment with progestogens 447 
should be discussed. Surgery is obviously the only reasonable choice when large and/or doubtful 448 
endometriomas are present.  449 
   450 
7.  RISK-REDUCING MEDICAL TREATMENT IN PERIMENOPAUSAL WOMEN 451 
Prolonged OC use is associated with a major reduction in the risk of developing an endometrioma 452 
[70,71]. This effect seems to be due to ovulation inhibition, as endometriomas have been 453 
demonstrated to derive from corpora lutea [72]. Therefore, OC and progestogens should 454 
theoretically reduce the risk of both, ENOC and CCOC in women with a history of endometriosis, 455 
but without current endometriomas. This risk-reducing effect seems an important added value of 456 
OC and progestogens in symptomatic endometriosis patients, even in the late reproductive years. 457 
 Moreover, according to Kim [2], the carcinogenic process leading to ENOC is primarily an 458 
estrogen-rich, progesterone-poor hormonal environment, whereas persistent oxidative stress 459 
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induced by a high intra-cystic level of heme and free iron may result in stress-resistant type such as 460 
CCOC. Thus, in theory, OC and progestogens use for prolonged periods of time in women who 461 
already have endometriomas may reduce the risk of mainly receptor-positive ENOC to a greater 462 
extent with respect to the risk of mainly receptor-negative CCOC. However, there are currently no 463 
data to support this hypothesis.  464 
 Modugno et al. [73], after pooling data from four population-based case-control studies on 465 
epithelial ovarian cancer comprising 2098 cases and 2953 control subjects, observed that use of 466 
OCs for >10 years was associated with a major reduction in ovarian cancer risk among women with 467 
endometriosis (odds ratio, 0.21; 95% CI, 0.08-0.58). Unfortunately, information on the effect of OC 468 
specifically on EAOC was not available. Actually, it seems difficult to define differences in the 469 
effect of OC on various ovarian cancer histotypes, and it may not be excluded that the results were 470 
largely due to a reduction in risk of HGSOC, similarly to what has been observed in the general 471 
population [74,75]. 472 
 Independently of histotypes, the reduction in ovarian cancer risk in endometriosis patients 473 
refers to OC use before menopause. In premenopausal women with a history of endometriosis and 474 
without current endometriomas, prolonged OC and progestogen use should be suggested until the 475 
natural menopause is reached, as the reduction in risk is directly related with duration of use. In 476 
addition, this protective effect extends for decades after OC use are discontinued [74,76]. In the 477 
model developed by Pearce et al. [76], OC use was essentially absent among the women at higher 478 
(> 4%) lifetime ovarian cancer risk (2015). There is no rationale supporting the use of hormonal 479 
treatments after menopause, neither as a preventive nor as a therapeutic measure. 480 
 481 
8.  SURVEILLANCE OR RISK-REDUCING SURGICAL TREATMENT IN 482 
PERIMENOPAUSAL WOMEN WITH A HISTORY OF ENDOMETRIOSIS BUT WITHOUT 483 
ENDOMETRIOMAS?  484 
i) Surveillance 485 
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The potential benefits of surveillance of the population of asymptomatic women with a previous 486 
diagnosis of endometriosis but without endometriomas are currently unknown. It is not possible to 487 
exclude that periodic assessment in a population at higher risk according to risk profiling models 488 
similar to that developed by Pearce et al. [76] may result in a reduction in mortality from ENOC 489 
and CCOC, also considering the different pathogenesis and natural history with respect to HGSOC. 490 
In fact, STIC, the precursor lesion of HGSOC, is so small that TVUS cannot detect it. The situation 491 
is different for EAOC, because they usually develop from epithelial atypia within ovarian 492 
endometriomas and are initially confined to one ovary. Therefore, in the case of ENOC and CCOC, 493 
detecting a de-novo ovarian cyst with TVUS characteristics of an endometrioma in women at 494 
increased risk, may allow timely surgery with eradication of stage I disease (or suspicious cysts 495 
without overt carcinomas) without extra-ovarian dissemination and with good long-term prognosis. 496 
However, given that type I tumors account for only 10% of the deaths from ovarian cancer, it is 497 
unclear if a prevention strategy aimed at identifying early EAOC would impact on the overall 498 
mortality from ovarian cancer.  499 
 The conceptual premise for such a surveillance program in premenopausal endometriosis 500 
patients, is that all women with newly detected endometriomas after the age of 45 years should 501 
undergo removal of the affected ovary and, when there is no pregnancy desire, also of both 502 
fallopian tubes. This would reduce not only the risk of EAOC, but also of HGSOC, thus increasing 503 
the benefit of periodic assessment.  504 
ii) Risk-reducing surgical treatment 505 
With “risk-reducing surgical treatment” we here refer to a patient population with a previous 506 
diagnosis of endometriosis/endometriomas, but with no current evidence of endometriotic ovarian 507 
cysts, and the question to be answered is whether women with a history of endometriosis but 508 
without ovarian endometriomas at TVUS should undergo prophylactic salpingo-oophorectomy 509 
when approaching the natural menopause. 510 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Vercellini et al., 21
 In the risk profiling model developed by Pearce et al. [76], five risk and protective factors 511 
were taken into account (i.e., OC use, parity, tubal ligation, endometriosis, and first-degree family 512 
history of ovarian cancer in conjunction with a genetic risk score) to define the distribution of 513 
lifetime ovarian cancer risk in the general population of up to age 85 for non-Hispanic white 514 
women. Risk/protective factor profiles were developed combining the distribution of these variable, 515 
considering the relative risks derived from published data, and using control data derived from four 516 
representative population-based U.S. studies. The estimated lifetime ovarian cancer risk for 214 517 
combinations of risk/protective factors ranged from 0.35% (95% CI, 0.29–0.42) to 8.78% (95% CI, 518 
7.10–10.9). In the higher quintile genetic risk scores, most women with lifetime risk ranging from 519 
4% to 8% had a self-reported history of endometriosis. As an example, nulliparous endometriosis 520 
patients with a negative family history for ovarian cancer and who did not undergo tubal ligation, 521 
have a lifetime risk of 4.03% (95% CI, 3.29%-4.94%) if they used OC for 1-4 years, and of 4.40% 522 
(95% CI, 3.71%-5.20%) in case they did not use OC. Most other reported combinations of factors 523 
are associated with even greater lifetime ovarian cancer risks, with point estimates ranging from 524 
4.81% to 7.99%. However, in routine practice the background genetic risk of endometriosis patients 525 
is usually unknown. Moreover, the frequency of women included in subgroups at higher ovarian 526 
cancer risk is very low, ranging from 0.02% to 0.11% of the general population [76] (Pearce 2015). 527 
Finally, external validation of the model by Pearce et al. [76] is lacking. 528 
 Manchanda et al. [77] conducted a healthcare economy analysis to define risk thresholds at 529 
which risk-reducing salpingo-oophorectomy can be cost-effective for the prevention of sporadic 530 
ovarian cancer in lower risk (BRCA negative) women aged 51 years. A decision-analytic model 531 
was developed to compare the costs and effects of offering risk-reducing salpingo-oophorectomy 532 
for 2%, 4%, 5%, 6%, 8% and 10% lifetime ovarian cancer risk thresholds. At the 2% ovarian cancer 533 
risk level, routine risk-reducing salpingo-oophorectomy does not save more quality-adjusted life 534 
years (QALY) and is not cost-effective. At a 4% ovarian cancer risk level, risk-reducing salpingo-535 
oophorectomy saves more QALYs but is not cost-effective at the incremental cost-effectiveness 536 
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ratio = £25,577, which is above the £20,000 U.K. ($ 26,650; €22,605) National Institute for Health 537 
and Care Excellence (NICE) threshold. However, at risk thresholds of ≥5%, risk-reducing salpingo-538 
oophorectomy saves more life-years and QALYs and is highly cost-effective. According to this 539 
model, and based on the lifetime ovarian cancer risk estimates reported by Pearce et al. [76], risk-540 
reducing bilateral salpingo-oophorectomy appears cost-effective only in women with endometriosis 541 
considered at high risk.  542 
 In the NICE guideline NG73 a suggestion regarding this specific area of endometriosis 543 
management was not deemed opportune because, as an absolute risk is difficult to quantify, 544 
“recommendations would not aid decision making, would cause anxiety in women with 545 
endometriosis and could be misconstrued, for example women seeking treatments (such as removal 546 
of the ovaries) that this small risk increase would not warrant”. Moreover, the Committee also 547 
stated “the potential harms associated with misinterpretation or over-interpretation of any 548 
recommendation based on this data would outweigh any benefits conferred by women being 549 
specifically informed about this data. This may lead to unnecessary procedures” [78, pages 116-550 
118]. The above position refers to women with endometriosis in general, and not to those with 551 
current ovarian endometriomas. 552 
 Overall, no sufficiently robust data are available to justify systematic risk-reducing salpingo-553 
oophorectomy in all women with a previous diagnosis of endometriosis, but without current 554 
evidence of endometriomas. Thus, this preventive measure should be discussed only with women at 555 
highly increased risk, such as those who report a positive family history of ovarian cancer, of 556 
infertility, and who have never used OC. 557 
 A special situation is when a histologic diagnosis of cytological and/or structural atypia has 558 
been made on a previously excised endometrioma, and the ovary has not been removed because of 559 
pregnancy desire. Although cystectomy likely eradicated the lesion, persisting predisposing factors 560 
may pose that woman at high risk of developing a EAOC, thus it seems prudent to discuss 561 
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prophylactic bilateral salpingo-oophorectomy after the age of 45 years even if the ovaries are 562 
normal at TVUS and serum CA 125 and HE4 levels are not increased [24].  563 
 According to available studies, atypical endometriosis foci are detected in 1%–3% of 564 
ovarian endometriotic cysts [79-81]. However, it is unclear whether those endometriomas were all 565 
judged preoperatively as low-risk, or whether also endometriomas with suspicious findings were 566 
included. Moreover, frequencies were not reported according to strata of age, and it is not possible 567 
to exclude that prevalence rates may be directly related with patient age. In a series of 874 568 
endometriomas without suspicious findings at preoperative TVUS removed in 516 patients, the 569 
prevalence of true atypical endometriosis was 1.0% (95% CI, 0.5% to 1.9%) based on the number 570 
of cysts, and 1.7% (95% CI, 0.9% to 3.3%) based on the number of women [53]. 571 
 An additional problem here is defining the rate of progression of atypical endometriosis 572 
toward CCOC and ENOC. In fact, it is accepted that only a fraction of precursor lesions progress 573 
toward frank malignancy, and this figure would be important in order to plan effective prevention 574 
strategies.  575 
 576 
9.  SCREENING FOR ASYMPTOMATIC ENDOMETRIOMAS BETWEEN PREVENTION 577 
AND OVERDIAGNOSIS 578 
Screening has been defined by the UK National Screening Committee as “the systematic 579 
application of a test or enquiry to identify individuals at sufficient risk of a specific disorder to 580 
warrant further investigation or direct preventive action, amongst persons who have not sought 581 
medical attention on account of symptoms of that disorder” [82]. The main objective of screening 582 
for ovarian cancer is to decrease the number of deaths from this disease. A secondary aim of 583 
screening is to increase the life expectancy of women who develop ovarian cancer [83]. The 584 
modality through which screening should decrease mortality is mostly by identifying pre-neoplastic 585 
lesions before they become overt ovarian cancer; the modality through which screening should 586 
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increase life expectancy is by allowing detection of already developed ovarian cancer when it is still 587 
confined within the ovary. 588 
 Thus, given that superficial and deep peritoneal endometriosis very rarely undergo 589 
malignant transformation, any screening program aimed at reducing mortality from EAOC should 590 
be targeted at detecting endometriotic cysts with atypical lesions, as well as stage I EAOC, in the 591 
general population. Unfortunately, screening programs for ovarian cancer have so far been 592 
disappointing. Results from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening 593 
trial indicated no mortality benefit and added morbidity due to increased surgical intervention [84]. 594 
Extended follow-up (median, 14,7 years) of the PLCO trial did not yielded more favorable results 595 
from screening for ovarian cancer with CA-125 and TVUS [85]. Recently, even the results of the 596 
UK collaborative trial of ovarian cancer screening (UKCTOCS) [86] have been heavily questioned 597 
based on methodological and other aspects [83]. Thus, because a reduction in mortality from 598 
ovarian cancer as a result of screening has not been documented, it is not routinely offered in the 599 
general population tout court, independently of ovarian cancer histotypes [77,83]. Indeed, the 600 
PLCO and the UKCTOCS   screening trials obviously were not limited to the detection of HGSOC 601 
and, within the framework of such strategies, all suspicious ovarian lesions, including 602 
endometriosis-related tumors, were surgically removed. Despite this, survival has not changed. 603 
 Beyond good intentions, any screening strategy should translate into a demonstrable 604 
reduction in disease-specific mortality, although many epidemiologists would argue that the effect 605 
of any screening should be reflected in a reduction of all-cause mortality. Importantly, health 606 
economy evaluations should be conducted in order to assess the efficiency of any prevention 607 
measure, that is, the effect of an intervention in relation to the resources it consumes (is it worth the 608 
effort?), before fostering its implementation into clinical practice. 609 
 With regard to the possibility of screening for EAOC, the NICE guideline NG73 committee 610 
considered “that there is no national screening available for ovarian cancer and that there is no 611 
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clear management plan that would help to reduce a possible small increased risk [in women with 612 
endometriosis]” [78, page 116]. 613 
 614 
10. THE CENTRAL ROLE OF INFORMED PATIENTS: HOW TO COMMUNICATE THE 615 
RISK 616 
Hazel Thornton wrote an enlightening editorial on the practical and ethical implications of different 617 
modalities to communicate the benefits, harms, and risks to patients [87]. Physicians must 618 
understand statistics and their meaning, know how to access reliable information, and develop the 619 
capability of communicating the relevant information in a clear and easily comprehensible manner. 620 
Without these premises, patient-centered medicine is simply impracticable. There is no single 621 
approach to management of perimenopausal women with small endometriomas, and the pros and 622 
cons of surgery and strict surveillance in different clinical conditions should be impartially 623 
explained. The temptation for both parties to “do something” and thus chose extirpative surgery is 624 
expected, but may not always be the best option in high surgical risk patients at low EAOC risk 625 
according to risk profiling models. Uncertainties should be addressed without fear of losing patient 626 
trust. Representing evidence as natural frequencies fosters greater insight than percentages or 627 
probabilities. Relative risks should never be used as they may convey a distorted information. 628 
According to Thornton, worry can be manipulated also by the labelling of outcomes.  629 
 The most controversial issue is probably risk-reducing salpingo-oophorectomy in the 630 
absence of TVUS detected endometriomas. Patient should know that the increase in risk, in 631 
absolute terms, is around half of a point percentage of developing an ovarian cancer and a third of a 632 
point percentage of dying from ovarian cancer compared with the general female population 633 
without a history of endometriosis. In other words, they should be informed that, rounding up, their 634 
lifetime probability of not developing an ovarian cancer is about 98% instead of 99%. When 635 
counseling women, several variables should be discussed, including factors that may impact on the 636 
risk of developing EAOC, such as prolonged use of OC or progestogens, parity, and family history. 637 
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Patients should also be invited to consider the additional surgical risk associated with previous 638 
surgical procedures, as well as with individual factors such as severe co-morbidities or obesity. 639 
 Manchanda et al. suggest the development of patient decision aids to facilitate 640 
understanding of risk [77].  Specific informed consent forms for different clinical conditions would 641 
need to be elaborated as well. According to Pearce et al. [76], “the precise lifetime risk at which a 642 
woman would consider a risk-reducing salpingo-oophorectomy is a matter to be decided by the 643 
woman in consultation with her physician. For women who are at, for example, three times the 644 
average lifetime risk of ovarian cancer (4.11% vs. 1.37%), such a discussion might be warranted”.  645 
 However, only a minority of endometriosis patient without endometriomas is at such highly 646 
increased risk. Indeed, the NICE Committee maintained “there needs to be a balance between 647 
women being fully informed about their condition (including related risks), with rationales for not 648 
encouraging unnecessary treatments” [78, page 116]. 649 
650 
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SUMMARY 651 
The lifetime risk of ovarian cancer is increased from 1.4% in the general population to about 1.9% 652 
in women with endometriosis. The risk of clear cell and endometrioid ovarian cancer is, 653 
respectively, tripled and doubled in women with endometriosis. These histotypes account for 654 
approximately 20% of all ovarian cancer and < 10% of deaths from ovarian cancer. Contrarily to 655 
clear cell tumors, endometrioid cancers are generally estrogen sensitive and associated with 656 
hormonal risk factors. Clear cell ovarian cancers may be caused by the mutagenic content of 657 
endometriomas, rich of free heme- and catalytic iron-derived reactive oxygen species. Atypical 658 
endometriosis, observed in 1-3% of endometriomas excised in premenopausal women, is the 659 
intermediate precursor lesion that links typical endometriosis and clear cell/endometrioid tumors. 660 
Oral contraceptive use for >10 years is associated with about 80% reduction in ovarian cancer risk 661 
among women with endometriosis. Surveillance ± progestogen treatment or surgery should be 662 
discussed in perimenopausal women with small typical endometriomas. If surgery is chosen in 663 
women not wishing conception, removal of affected ovaries, rather than cystectomy, together with 664 
bilateral salpingectomy should be performed, especially in case of long-standing or recurrent 665 
endometriomas. In most perimenopausal women with a history of endometriosis but without 666 
endometriomas, surveillance instead of risk-reducing bilateral salpingo-oophorectomy seems 667 
advisable. Hypothetically, risk-reducing salpingo-oophorectomy may benefit patients at particularly 668 
increased risk, but supporting evidence is limited. Risk profiling models and decision aids may 669 
assist patients in their choice. Screening of the general population to detect asymptomatic 670 
endometriomas is unlikely to reduce disease-specific mortality. 671 
672 
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Practice Points:  691 
• Endometriosis is associated with a three-fold increase in risk of endometrioid and clear-cell 692 
ovarian cancer 693 
• Atypical endometriosis is the precursor lesion of endometriosis-associated ovarian cancers 694 
and is observed in 1-3% of ovarian endometriomas removed in premenopausal women 695 
• The lifetime risk of ovarian cancer in women with a history of endometriosis is about 1.9% 696 
compared with 1.4% in the general population 697 
• Long periods (≥ 10 years) of oral contraceptive use greatly reduce the risk of ovarian cancer 698 
in women with a history of endometriosis 699 
• In most women with a history of endometriosis but without ultrasonographic evidence of 700 
endometriomas, surveillance rather than risk-reducing salpingo-oophorectomy seems 701 
advisable 702 
• In women with small, long-standing typical endometriomas, removal of the affected 703 
ovary/ovaries and bilateral salpingectomy can be considered when approaching the 704 
menopause 705 
 706 
Research Agenda:  707 
• The potential benefit of risk-reducing salpingo-oophorectomy in women with a history of 708 
endometriosis should be better defined according to different risk profiles 709 
• Potential benefits, potential harms, and healthcare economic aspects of prolonged 710 
surveillance in asymptomatic women with a history of endometriosis but without current 711 
endometriomas should be assessed in a randomized, controlled trial 712 
• Early markers of the malignant potential of endometriomas removed at conservative surgery 713 
should be identified 714 
• Surveillance and management strategies for women with a previous histologic diagnosis of 715 
atypical endometriomas should be defined 716 
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• Patient decision aids should be developed to facilitate women comprehension of actual risks 717 
and support shared decision-making in different clinical conditions 718 
719 
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TABLE 1.  Common molecular patterns in endometriosis-associated carcinomas. 960 
Endometriosis-associated ovarian clear cell 
carcinoma 
Endometriosis-associated ovarian 
endometrioid carcinoma 
Mutations in 
• ARID1A 
• PIK3CA 
• CTNNB1 
• PTEN 
 
Expression of 
• HNF-1beta     ++ 
• BAF250a        -- 
• Napsin A        ++ 
• Nuclear ERα   -- 
• Cytoplasmatic ERβ2   -- 
• Cytoplasmatic ERβ5   -- 
 
Mutations in 
• PTEN 
• CTNNB1 
• KRAS 
• ARID1A 
• PIK3CA 
• PPP2R1A 
 
Expression of 
• BAF250a      -- 
961 
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TABLE 2. A conceptual definition of premalignant lesions based on five diagnostic criteria 962 
developed during the National Cancer Institute Consensus Conference on Precancer.  963 
November 8–9, 2004, George Washington University Medical Center, Washington, DC. 964 
_______________________________________________________________________________ 965 
(1)  Evidence exists that the precancer is associated with an increased risk of cancer. 966 
(2)  When a precancer progresses to cancer, the resulting cancer arises from cells within the 967 
 precancer. 968 
(3)  A precancer is different from the normal tissue from which it arises. 969 
(4)  A precancer is different from the cancer into which it develops, although it has some, but not 970 
 all, of the molecular and phenotypic properties that characterize the cancer. 971 
(5)  There is a method by which the precancer can be diagnosed. 972 
_______________________________________________________________________________ 973 
From Berman et al. [52] 974 
975 
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LEGEND TO FIGURE 1 976 
 977 
1A. A high-power image of an endometriotic cyst wall with atypical cells showing eosinophilic 978 
cytoplasm, large hyperchromatic (arrows) or pale nuclei with moderate pleomorphism, increased 979 
nucleus-to-cytoplasm ratio, mitosis, and cellular crowding, stratification, or tufting.  980 
(hematoxylin and eosin, original magnification 40x). 981 
 982 
1B.  High-power image of an endometriotic cyst wall showing hyperplastic epithelial cells 983 
exhibiting uniform reactive atypia with variable nuclear features: increased nucleus-to-cytoplasm 984 
ratio, pale nuclei with slight pleomorphism, prominent nucleoli (arrows) and acute inflammatory 985 
cells within the epithelium (dotted arrows). The endometriotic stromal cells are admixed with acute 986 
and chronic inflammatory cells; * prominent capillaries; ** hemosiderin laden macrophages. 987 
(hematoxylin and eosin, original magnification 40x). 988 
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HIGHLIGHTS 
 
• Endometriosis is associated with a moderate increase in ovarian cancer risk 
• In women with endometriosis the risk of endometrioid ovarian cancer is doubled 
• The risk of ovarian cancer is associated with age and endometriotic cyst dimension 
